BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, September 28, 2023
Home » Blogs » BioWorld Perspectives » Drug Shortages? We Ain’t Seen Nothin’ Yet

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld / Oncology / Biosimilar

Drug Shortages? We Ain’t Seen Nothin’ Yet

Oct. 6, 2011
By Mari Serebrov
No Comments

You think the drug shortage is a devil now

Just wait around a few years

’Cause you ain’t seen nothin’ yet.

When that biosimilar pathway begins to flash

Those big green dollar signs,

You’ll know, you’ll know, you’ll know, you just ain’t seen nothin’ yet.

Those biosimilars will turn your heart away from the old drugs of yesterday.

You’ll think you have it comin’, and you’ll want it that way.

You’ll say big profits are good profits, so you’ll take what you can get.

B-B-B-Baby, you ain’t seen n-n-n-nothin’ yet.

Patients will go to the doctor, and he’ll tell them of a cure.

But they won’t be feelin’ better, ’cause it’ll be the one they just can’t get.

They’ll wait, they’ll wait, they’ll wait. And then they’ll take whatever they can get.

B-B-B-Baby, we ain’t seen n-n-n-nothin’ yet.

With all due apologies to Bachman Turner Overdrive (listen to the classic rock tune here), I’m afraid we ain’t seen nothing yet when it comes to drug shortages. As we’ve reported in BioWorld Today, the bottom line is often behind a drugmaker’s decision to stop making older, off-patent drugs with low profit margins. Making a drug that sells for 48 cents a vial just doesn’t make good business sense.

It will make even less ‘cents’ when the biosimilar pathway really opens up. Many generic and big pharma companies are already developing biosimilars, lured by pricing that could be 80 percent of the innovator biologic, which can sell for thousands of dollars.

As they spend more on biosimilars, these companies may be even less committed to providing the tried and true, older drugs. Thus, my sad refrain:

 

You ain't seen nothin' yet,

B-B-B-Baby, you just ain't seen n-n-n-nothin' yet,

Here's to the drugs we're not gonna get,

B-B-B-Baby, you just ain't seen n-n-n-nothin' yet

If you're thinkin' they ain't gonna be around, that's right.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Sept. 27, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for September 27, 2023.
  • 3D illustration of cancer in crosshairs

    Dato data lack means upside for Gilead; Padcev 'must-win' does win

    BioWorld
    Upbeat phase III findings outweighed less encouraging late-stage trial news, as big pharma provided a mixed bag of cancer findings – with one data batch to form...
  • Illustration of Alzheimer’s in the brain.

    Study identifies cause of death for Alzheimer’s neurons

    BioWorld
    By creating a new mouse model of Alzheimer’s disease that better recapitulated how the disease plays out in humans, investigators at KU Leuven have gained new...
  • Apple Computer Inc. logo

    Apple scores win over Masimo for patents for physiological detectors, but ITC decision awaits

    BioWorld MedTech
    Apple Inc., of Cupertino, Calif., has prevailed over Masimo Corp., in a ruling at the U.S. Court of Appeals for the Federal Circuit, an outcome that invalidated...
BioFuture ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing